Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Update

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the recipient of a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 248,500 shares, a decrease of 88.5% from the June 30th total of 2,160,000 shares. Based on an average daily volume of 396,700 shares, the days-to-cover ratio is presently 0.6 days.

Institutional Trading of Aligos Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Opaleye Management Inc. lifted its stake in Aligos Therapeutics by 25.7% in the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock worth $1,597,000 after acquiring an additional 333,000 shares during the period. Acadian Asset Management LLC lifted its stake in Aligos Therapeutics by 17.6% in the first quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock worth $644,000 after acquiring an additional 98,628 shares during the period. Altitude Crest Partners Inc. purchased a new stake in Aligos Therapeutics in the fourth quarter worth $1,889,000. Armistice Capital LLC purchased a new stake in Aligos Therapeutics in the fourth quarter worth $4,538,000. Finally, Vanguard Group Inc. lifted its stake in Aligos Therapeutics by 1.6% in the third quarter. Vanguard Group Inc. now owns 1,010,617 shares of the company’s stock worth $755,000 after acquiring an additional 15,905 shares during the period. Hedge funds and other institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Trading Down 5.2 %

Shares of NASDAQ:ALGS traded down $0.03 during trading on Thursday, reaching $0.51. 26,281 shares of the company traded hands, compared to its average volume of 371,685. The firm has a market capitalization of $39.92 million, a price-to-earnings ratio of -0.41 and a beta of 2.19. Aligos Therapeutics has a 52-week low of $0.35 and a 52-week high of $1.20. The business’s fifty day moving average is $0.52 and its 200-day moving average is $0.71.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). The company had revenue of $0.99 million for the quarter. Aligos Therapeutics had a negative net margin of 783.72% and a negative return on equity of 144.16%. On average, sell-side analysts predict that Aligos Therapeutics will post -0.73 earnings per share for the current fiscal year.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).